{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-25-000010","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.178790+00:00","generated_at":"2026-05-20T02:58:18.293497+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Phase 3 PANOVA-3 trial meets primary endpoint; median OS improved to 16.2 vs 14.2 months (HR 0.82, p=0.039)","bullets":["Median overall survival 16.2 months with TTFields + GnP vs 14.2 months for GnP alone; HR 0.82, p=0.039.","One-year survival rate 68.1% vs 60.2% (p=0.029).","Median pain-free survival 15.2 months vs 9.1 months; 6.1-month extension (HR 0.74, p=0.027).","TTFields therapy well-tolerated with mild to moderate skin adverse events; no new safety signals.","Company plans to file for FDA PMA approval in second half of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-25-000010","json":"https://secwatch.observer/filing/0001645113-25-000010.json","markdown":"https://secwatch.observer/filing/0001645113-25-000010.md","text":"https://secwatch.observer/filing/0001645113-25-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511325000010/0001645113-25-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511325000010/nvcr-20250531.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T02:58:18.293497+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}